Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons dr. S.P.C. Lam

Publicaties

Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial

Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: A phenomics approach

Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure

Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical Trial

Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors

Statins and risks of dementia among patients with heart failure: a population-based retrospective cohort study in Hong Kong

Age-Dependent Association Between Modifiable Risk Factors and Incident Cardiovascular Disease

Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy

Association Between Diabetes, Chronic Kidney Disease, and Outcomes in People With Heart Failure From Asia

Lees meer

Pers/media

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Wat is nieuw in de 2021 ESC HF richtlijn wat betreft patiënten met EF>40%?